# Xuanzhu Biopharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xuanzhu-biopharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.xuanzhubio.com
- Total disclosed funding: $213M
- Latest round: Series B (Jan 3, 2022)
- Investors on record: 13

## About

Established in 2002 and based in Jinan, China, Xuanzhu Biopharmaceutical Co., Ltd. is a new molecular entity and innovative drug developer, focusing on tumors, metabolic diseases, infections and other fields. The company management team is mainly composed of doctors who are engaged in innovative drug design, compound synthesis, early screening and evaluation, preclinical pharmacology and toxicology research, and clinical pharmacology research and have more than 10 years of work experience. In 2018, the company obtained the national class 1 new drug XZP-3621 obtained the phase I-III clinical approval, the national class 1 new drug KBP-5081 obtained the II-III clinical approval, started the phase II clinical trial, and the national class 1 new drug KBP-3571 obtained the II-III phase clinical approval.
The company is mainly engaged in the research and development of new molecular entity drugs. The research fields mainly include the field of anti-infection, anti-cardiovascular and metabolic diseases, anti-tumor and other cutting-edge new drug research and development fields. At present, a completely new drug research and development system has been formed, with a professional platform for new drug structure design, evaluation, candidate compound establishment, clinical research, and new drug marketing application. The company self-developed products such as metabolic innovative drug XZP-5610, lung cancer treatment drugs XZP-5809 and XZP-3621, tumor treatment drugs XZP-5955, XZP-P107, XZP-P270 and so on.
Revenue is generated through licensing of drug candidates, strategic partnerships, and commercialization of proprietary therapeutics. The company also benefit from milestone payments and royalties from co-development agreements.

## Funding rounds

- Series B, Jan 3, 2022, $96M — Bank of China Group Investment, Efung Capital, DNV Capital, Haier Capital, Zhongji Investment, HY Capital, Sunshine Life Insurance, Financial Holding Group, SDIC Taikang Trust, Wanxin Capital, Herui Venture Capital, Taijin Capital
- Series A, Aug 24, 2020, $117M — China Merchants Capital

## Investors

- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series A
- Bank of China Group Investment — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- DNV Capital (https://capitalatlas.ai/funds/dnv-capital) — Series B
- Haier Capital (https://capitalatlas.ai/funds/haier-capital) — Series B
- Zhongji Investment (https://capitalatlas.ai/funds/zhongji-investment) — Series B
- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Series B
- Sunshine Life Insurance — Series B
- Financial Holding Group (https://capitalatlas.ai/funds/financial-holding-group) — Series B
- SDIC Taikang Trust — Series B
- Wanxin Capital — Series B
- Herui Venture Capital (https://capitalatlas.ai/funds/herui-venture-capital) — Series B
- Taijin Capital — Series B